Millipore Sigma Vibrant Logo
Attention: We have moved. EMD Millipore products are no longer available for purchase on emdmillipore.com.Learn More

AB9676 Anti-Tau phospho Threonine 205 Antibody

View Products on Sigmaaldrich.com
AB9676
100 µL  
Purchase on Sigma-Aldrich

Special Offers

Overview

Replacement Information

Key Specifications Table

Species ReactivityKey ApplicationsHostFormatAntibody Type
HWBRbAffinity PurifiedPolyclonal Antibody
Description
Catalogue NumberAB9676
Brand Family Chemicon®
Trade Name
  • Chemicon
DescriptionAnti-Tau phospho Threonine 205 Antibody
Background InformationTau is a neuronal microtubule-associated protein found predominantly on axons and functions to promote tubulin polymerization and stabilize microtubules. Tau, in its hyperphosphorylated form, is the major component of paired helical filaments (PHF), the building block of neurofibrillary lesions in Alzheimer's disease (AD) brain. Hyperphosphorylated Tau is also found in neurofibrillary lesions in a range of other central nervous system disorders. Hyperphosphorylation impairs the microtubule binding function of Tau, resulting in the destabilization of microtubules in AD brains, ultimately leading to the degeneration of the affected neurons. Numerous serine/threonine kinases, including GSK-3beta, protein kinase A (PKA), cyclin-dependent kinase 5 (cdk5) and casein kinase II (CK2), phosphorylate Tau. Phosphorylation of threonine 205 is catalyzed GSK-3beta and cdk5 in vitro.
References
Product Information
FormatAffinity Purified
PresentationAffinity purified immunoglobulin. Liquid in Dulbecco's PBS (without Mg2+ and Ca2+), pH 7.3, 50% glycerol with 1.0 mg/mL BSA and 0.05% sodium azide.
Quality LevelMQ100
Applications
ApplicationThis Anti-Tau phospho Threonine 205 Antibody is validated for use in WB for the detection of Tau phospho Threonine 205.
Key Applications
  • Western Blotting
Application NotesWestern blot: 1:1,000. Suggested blocking buffer is 5% BSA-TBST for one hour at room temperature. Suggested antibody dilution buffer is 3% BSA-TBST. Suggested antibody incubation time is 2 hours at room temperature..


Optimal working dilutions must be determined by the end user.
Biological Information
ImmunogenSynthetic peptide of amino acids surrounding the phosphoThreonine 205 site of human Tau.
HostRabbit
SpecificityTau phosphoThreonine 205. The antibody recognizes Tau pThreonine 205 in samples of recombinant human Tau treated with GSK-3beta for 45 minutes.. The reactivity of the antibody is blocked with the pThreonine 205 peptide but not the non-phosphopeptide or a generic phosphoThreonine-containing peptide.
Species Reactivity
  • Human
Antibody TypePolyclonal Antibody
Entrez Gene Number
Entrez Gene SummaryThis gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.
Gene Symbol
  • MAPT
  • MTBT2
  • MAPTL
  • PHF-tau
  • tau
  • DDPAC
  • FTDP-17
  • MGC138549
  • MSTD
  • TAU
  • FLJ31424
  • MTBT1
  • PPND
Modifications
  • Phosphorylation
UniProt Number
UniProt SummaryFUNCTION: SwissProt: P10636 # Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N- terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
SIZE: 758 amino acids; 78878 Da
SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated.
SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cell membrane. Note=Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
DOMAIN: SwissProt: P10636 The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
PTM: Phosphorylation at serine and threonine residues in S-P or T- P motifs by proline-directed protein kinases (PDPK: CDC2, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K- X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser- 622, Ser-641 and Ser-673 in several isoforms during mitosis. & Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur. & Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
DISEASE: SwissProt: P10636 # In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). & Defects in MAPT are a cause of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP17) [MIM:600274, 172700]; also called frontotemporal dementia (FTD) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons. & Defects in MAPT are a cause of pallido-ponto-nigral degeneration (PPND) [MIM:168610]. The clinical features include ocular motility abnormalities, dystonia and urinary incontinence, besides progressive parkinsonism and dementia. & Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease. & Defects in MAPT are a cause of progressive supranuclear palsy (PSP) [MIM:601104, 260540]; also known as Steele-Richardson- Olszewski syndrome. PSP is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. & Defects in MAPT may be a cause of hereditary dysphasic disinhibition dementia (HDDD) [MIM:607485]. HDDD is a frontotemporal dementia characterized by progressive cognitive deficits with memory loss and personality changes, severe dysphasic disturbances leading to mutism, and hyperphagia.
SIMILARITY: Contains 4 Tau/MAP repeats.
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsMaintain at -20°C in undiluted for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles. Do not store in a self defrosting freezer.
Packaging Information
Material Size100 µL
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalog Number GTIN
AB9676 04053252333675

Documentation

Anti-Tau phospho Threonine 205 Antibody SDS

Title

Safety Data Sheet (SDS) 

Anti-Tau phospho Threonine 205 Antibody Certificates of Analysis

TitleLot Number
RABBIT ANTI-Tau phosphoThreonine 205 - 3415875 3415875
RABBIT ANTI-Tau phosphoThreonine 205 - 3732969 3732969
RABBIT ANTI-Tau phosphoThreonine 205 - 3894963 3894963
RABBIT ANTI-Tau phosphoThreonine 205 - 4119026 4119026
RABBIT ANTI-Tau phosphoThreonine 205 - 4131110 4131110
RABBIT ANTI-Tau phosphoThreonine 205 -2632595 2632595
RABBIT ANTI-Tau phosphoThreonine 205 POLYCLONAL ANTIBODY - 2069369 2069369
RABBIT ANTI-Tau phosphoThreonine 205 POLYCLONAL ANTIBODY - 2310374 2310374

References

Reference overviewPub Med ID
The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation.
Jämsä, A., et al.
Biochem. Biophys. Res. Comm., 319:993-1000 (2004)  2004

15184080 15184080
Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.
Liu, F., et al.
FEBS Lett., 530(1-3):209-214 (2002)  2002

12387894 12387894
Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein.
Alonso, A.D., et al.
J. Biol. Chem., 276(41):37967-37973 (2001)  2001

11495914 11495914
Distribution of tau protein kinase I/glycogen synthase kinase-3beta, phosphatases 2A and 2B, and phosphorylated tau in the developing rat brain.
Takahashi, M., et al.
Brain Res., 857(1-2):193-206 (2000)  2000

10700568 10700568
Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase.
Wang, J.Z., et al.
FEBS Lett., 436(1):28-34 (1998)  1998

9771888 9771888
Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein.
Reynolds, C H, et al.
J. Neurochem., 68: 1736-44 (1997)  1997

Show Abstract
9084448 9084448
Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.
Imahori, K. and T. Uchida
J. Biochem., 121:179-188 (1997)  1997

9089387 9089387
Reactivating kinase/p38 phosphorylates tau protein in vitro.
Reynolds, C.H., et al.
J. Neurochem., 69(1):191-198 (1997)  1997

9202310 9202310
Regulation of the phosphorylation state and microtubule-binding activity of tau by protein phosphatase 2A.
Sontag, E., et al.
Neuron , 17:1201-1207 (1996)  1996

8982166 8982166

Related Products & Applications

Product Families

Categories

Life Science Research > Antibodies and Assays > Primary Antibodies